209 related articles for article (PubMed ID: 32159854)
1. Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor-related cytotoxicity.
Patel A; Seraia E; Ebner D; Ryan AJ
Int J Cancer; 2020 Sep; 147(5):1474-1484. PubMed ID: 32159854
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
3. ATR inhibition rewires cellular signaling networks induced by replication stress.
Wagner SA; Oehler H; Voigt A; Dalic D; Freiwald A; Serve H; Beli P
Proteomics; 2016 Feb; 16(3):402-16. PubMed ID: 26572502
[TBL] [Abstract][Full Text] [Related]
4. Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway.
Majera D; Skrott Z; Chroma K; Merchut-Maya JM; Mistrik M; Bartek J
Cells; 2020 Feb; 9(2):. PubMed ID: 32085572
[TBL] [Abstract][Full Text] [Related]
5. Dual genome-wide CRISPR knockout and CRISPR activation screens identify mechanisms that regulate the resistance to multiple ATR inhibitors.
Schleicher EM; Dhoonmoon A; Jackson LM; Clements KE; Stump CL; Nicolae CM; Moldovan GL
PLoS Genet; 2020 Nov; 16(11):e1009176. PubMed ID: 33137164
[TBL] [Abstract][Full Text] [Related]
6. Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors.
Wang WT; Catto JW; Meuth M
Oncogene; 2015 May; 34(22):2887-96. PubMed ID: 25043304
[TBL] [Abstract][Full Text] [Related]
7. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
[TBL] [Abstract][Full Text] [Related]
8. ATR phosphorylates SMARCAL1 to prevent replication fork collapse.
Couch FB; Bansbach CE; Driscoll R; Luzwick JW; Glick GG; Bétous R; Carroll CM; Jung SY; Qin J; Cimprich KA; Cortez D
Genes Dev; 2013 Jul; 27(14):1610-23. PubMed ID: 23873943
[TBL] [Abstract][Full Text] [Related]
9. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
[TBL] [Abstract][Full Text] [Related]
10. Synergistic lethality between auranofin-induced oxidative DNA damage and ATR inhibition in cancer cells.
Zhang S; Zhao Y; Wang X; Qi C; Tian J; Zou Z
Life Sci; 2023 Nov; 332():122131. PubMed ID: 37778414
[TBL] [Abstract][Full Text] [Related]
11. S-phase-dependent p50/NF-кB1 phosphorylation in response to ATR and replication stress acts to maintain genomic stability.
Crawley CD; Kang S; Bernal GM; Wahlstrom JS; Voce DJ; Cahill KE; Garofalo A; Raleigh DR; Weichselbaum RR; Yamini B
Cell Cycle; 2015; 14(4):566-76. PubMed ID: 25590437
[TBL] [Abstract][Full Text] [Related]
12. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
Ngoi NY; Sundararajan V; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
[TBL] [Abstract][Full Text] [Related]
13. Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-related.
Beggs KM; Maiuri AR; Fullerton AM; Poulsen KL; Breier AB; Ganey PE; Roth RA
Toxicology; 2015 May; 331():35-46. PubMed ID: 25748550
[TBL] [Abstract][Full Text] [Related]
14. ATM and ATR as therapeutic targets in cancer.
Weber AM; Ryan AJ
Pharmacol Ther; 2015 May; 149():124-38. PubMed ID: 25512053
[TBL] [Abstract][Full Text] [Related]
15. Targeting ATR in DNA damage response and cancer therapeutics.
Fokas E; Prevo R; Hammond EM; Brunner TB; McKenna WG; Muschel RJ
Cancer Treat Rev; 2014 Feb; 40(1):109-17. PubMed ID: 23583268
[TBL] [Abstract][Full Text] [Related]
16. Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress.
Lloyd RL; Urban V; Muñoz-Martínez F; Ayestaran I; Thomas JC; de Renty C; O'Connor MJ; Forment JV; Galanty Y; Jackson SP
Nucleic Acids Res; 2021 Sep; 49(15):8665-8683. PubMed ID: 34329458
[TBL] [Abstract][Full Text] [Related]
17. The Adenovirus E4orf4 Protein Provides a Novel Mechanism for Inhibition of the DNA Damage Response.
Brestovitsky A; Nebenzahl-Sharon K; Kechker P; Sharf R; Kleinberger T
PLoS Pathog; 2016 Feb; 12(2):e1005420. PubMed ID: 26867009
[TBL] [Abstract][Full Text] [Related]
18. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
19. Molecular Pathways: Targeting ATR in Cancer Therapy.
Karnitz LM; Zou L
Clin Cancer Res; 2015 Nov; 21(21):4780-5. PubMed ID: 26362996
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
